Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway

作者：Xu Jianmin; Walsh Stephanie B; Verney Zoe M; Kopelovich Levy; Elmets Craig A; Athar Mohammad^*

来源：Biochemical and Biophysical Research Communications, 2011, 408(3): 363-368.

DOI：10.1016/j.bbrc.2011.02.039

• Cyclosporine A
• Nonmelanoma skin cancer
• Immune suppression
• TAK1 signaling
• Nuclear factor kappa B

Cyclosporine A (CsA) is an immunosuppressive drug commonly used for maintaining chronic immune suppression in organ transplant recipients. It is known that patients receiving CsA manifest increased growth of aggressive non-melanoma skin cancers. However, the underlying mechanism by which CsA augments tumor growth is not fully understood. Here, we show that CsA augments the growth of A431 epidermoid carcinoma xenograft tumors by activating tumor growth factor beta-activated kinase1 (TAK1). The activation of TAK1 by CsA occurs at multiple levels by kinases ZMP, AMPK and IRAK. TAK1 forms heterodimeric complexes with TAK binding protein 1 and 2 (TAB1/TAB2) which in term activate nuclear factor kappa B (NF kappa B) and p38 MAP kinase. Transcriptional activation of NF kappa B is evidenced by IKK beta-mediated phosphorylation-dependent degradation of I kappa B and consequent nuclear translocation of p65. This also leads to enhancement in the expression of its transcriptional target genes cyclin D1, Bcl2 and COX-2. Similarly, activation of p38 leads to enhanced inflammation-related signaling shown by increased phosphorylation of MAPKAPK2 and which in turn phosphorylates its substrate HSP27. Activation of both NF kappa B and p38 MAP kinase provide mitogenic stimuli to augment the growth of SCCs.

• 出版日期2011-5-13